Africa: RTS,S Malaria Vaccine Reaches More Than 650 000 Children in Ghana, Kenya and Malawi Through Groundbreaking Pilot Programme


Malaria vaccine coverage through childhood immunization programme signals strong community demand for vaccine.

Two years on from the launch of a pilot programme, more than 1.7 million doses of the world’s first malaria vaccine have been administered in Ghana, Kenya and Malawi, benefitting more than 650 000 children with additional malaria protection.

The number of children reached in this relatively short period indicates strong community demand for the vaccine as well as the capacity of the countries’ child immunization programmes to deliver the vaccine on a novel schedule (4 doses up to about age 2 years).

At a time when global progress in malaria control has stalled, the protection provided by the RTS,S malaria vaccine, when added to currently recommended malaria control interventions, has the potential to save tens of thousands of lives per year.

“Ghana, Kenya and Malawi show that existing childhood vaccination platforms can effectively deliver the malaria vaccine to children, some of whom have not been able to access an insecticide treated bed net or other malaria prevention measures,” says Dr Kate O’Brien, WHO Director of the Department of Immunization, Vaccines and Biologicals. “This vaccine may be key to making malaria prevention more equitable, and to saving more lives.”

“Over the last 2 decades, we have achieved remarkable results with existing malaria control tools, averting more than 7 million deaths and 1.5 billion cases of the disease,” says Dr Pedro Alonso, Director of the WHO Global Malaria Programme. “However, progress towards key targets of our global malaria strategy remains off course. To get back on track, new tools are urgently needed – and malaria vaccines must be a critical component of the overall toolkit.”

Insights generated by the pilot implementation will inform a WHO recommendation on broader use of the vaccine across sub-Saharan Africa.  Global advisory bodies for immunization and malaria are expected to convene in October 2021 to review RTS,S data and consider whether to recommend wider use of the vaccine.